


Spotlight on Cost of Cancer Care

Case Study: Cost of cancer care per patient is driven by dose, schedule, and changes in drug cost. Total cost of care by indication is driven by the same factors plus change in number of patients receiving therapy in a given indication. Bevacizumab (Avastin; Genentech) average cost per patient per month and total cost per month has increased in all tumors but most significant and volatile in recently approved indications: kidney cancer and brain cancer.


Change in average ASP cost per patient per month: bevacizumab/all lines of therapy



Notes:

- » Change in cost per patient per month is indexed relative to the first month of observation and shown for a 36-month period
- » Cost per patient per month is average of mgs/pt/month multiplied by corresponding ASP price/mg

Change in total monthly ASP cost: bevacizumab/all lines of therapy



Notes:

- » Change in total monthly cost is indexed relative to the first month of observation and shown for a 36-month period
- » Monthly cost is sum of mgs administered to all patients in a given month and tumor multiplied by ASP price/mg

Average Sales Price (ASP) is calculated based on wholesale prices 2 quarters ago. ASP+6% is used to establish the ceiling for reimbursement. ASP+6% pricing data are publicly available at <http://www.cms.gov/McrPartBDrug-AvgSalesPrice/>. ASP price is assumed for all graphs.

About the Contributor

IntrinsiQ IntrinsiQ, LLC is the leading provider of medical oncology clinical information systems and the premier source of U.S. oncology data and analysis.